The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Celgene
Stock and Other Ownership Interests - Celgene
Travel, Accommodations, Expenses - Celgene
Nab-paclitaxel/gemcitabine first-line therapy in patients with metastatic pancreatic carcinoma and high-bilirubin levels: Data from the German QoliXane Pancreatic Cancer Registry.
 
Gerrit zur Hausen
Honoraria - Celgene
Travel, Accommodations, Expenses - Celgene
 
Oliver Waidmann
Consulting or Advisory Role - Bayer; Novartis; Roche
Research Funding - Medac; Novartis
Travel, Accommodations, Expenses - Abbvie; Bayer; Celgene; Gilead Sciences; Novartis; Teva
 
Marcus A. Woerns
Consulting or Advisory Role - Celgene
Speakers' Bureau - Celgene
 
Heinz-Gert Hoeffkes
No Relationships to Disclose
 
Steffen Doerfel
No Relationships to Disclose
 
Mark-Oliver Zahn
No Relationships to Disclose
 
Ali Aldaoud
No Relationships to Disclose
 
Martina Stauch
No Relationships to Disclose
 
Christoph Springfeld
Consulting or Advisory Role - Celgene
Travel, Accommodations, Expenses - Celgene
 
Nicolai Haertel
Research Funding - Celgene (Inst)
 
Alexander Reichart
No Relationships to Disclose
 
Claudia Pauligk
No Relationships to Disclose
 
Josefine Roemmler-Zehrer
No Relationships to Disclose
 
Ralf Hofheinz
No Relationships to Disclose
 
Salah-Eddin Al-Batran
Consulting or Advisory Role - Celgene; Lilly; Merck; Roche
Speakers' Bureau - Celgene; Lilly; Nordic Bioscience; Roche
Research Funding - Celgene; Hospira; Lilly; Medac; Novartis; Roche Pharma AG; Vifor Pharma